Daily Cosmetic Research Analysis
Today's most impactful studies span preventive dermatology and cosmetic safety. A double-blind RCT found no benefit of daily chlorhexidine wipes over soap-and-water for preventing diabetic foot complications. A crossover intervention identified diet—rather than personal care products—as a dominant source of ethyl paraben exposure, and a randomized trial showed urea cream does not prevent capecitabine-associated hand-foot syndrome.
Summary
Today's most impactful studies span preventive dermatology and cosmetic safety. A double-blind RCT found no benefit of daily chlorhexidine wipes over soap-and-water for preventing diabetic foot complications. A crossover intervention identified diet—rather than personal care products—as a dominant source of ethyl paraben exposure, and a randomized trial showed urea cream does not prevent capecitabine-associated hand-foot syndrome.
Research Themes
- Preventive dermatology randomized trials
- Cosmetic chemical exposure and safety
- Oncology supportive dermatology
Selected Articles
1. Chlorhexidine vs Routine Foot Washing to Prevent Diabetic Foot Ulcers: A Randomized Clinical Trial.
In a double-blind, placebo-controlled RCT of 175 high-risk veterans with diabetes, daily 2% chlorhexidine wipes did not reduce time to new foot complications versus soap-and-water wipes over 1 year. The intervention was well tolerated and adherence was high, with no product-related adverse events.
Impact: High-quality negative RCT evidence counters assumptions that antiseptic wipes prevent diabetic foot complications, informing preventive care strategies.
Clinical Implications: Routine use of chlorhexidine wipes for diabetic foot care should not be recommended solely for preventing ulcers, infection, or amputation; reinforce standard soap-and-water hygiene and comprehensive foot self-care education.
Key Findings
- No significant reduction in new foot complications with chlorhexidine vs control (12/88 [14%] vs 14/87 [16%]; HR 0.83, 95% CI 0.39–1.80).
- Median time to complication was 232 days (IQR 115–315) across groups.
- High adherence (83%) and no product-related adverse events over 1 year.
Methodological Strengths
- Double-blind, placebo-controlled randomized design with intention-to-treat analysis
- Registered trial (ClinicalTrials.gov NCT03503370) with clearly defined primary outcome
Limitations
- Single-center VA population limits generalizability
- Phase 2b with modest sample size may be underpowered for small effect sizes
Future Directions: Evaluate multifaceted foot-care interventions (education, offloading, footwear) and identify subgroups that might benefit from antiseptic strategies; explore pragmatic, multicenter designs.
IMPORTANCE: Foot ulcers are a common and feared complication for people with diabetes because 20% of foot ulcers become infected and lead to a lower extremity amputation. OBJECTIVE: To evaluate the effect of daily foot care using chlorhexidine wipes vs soap-and-water wipes for 1 year on the risk of developing new foot complications in veterans with diabetes. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, phase 2b randomized clinical trial was conducted at the Baltimore Veterans Affairs (VA) Medical Center between January 2019 to January 2023. Veterans were eligible if they had a diabetes diagnosis, were at high risk for diabetic foot complications, were ambulatory, had both feet, and did not have a current foot infection. Participants were randomly assigned 1:1 to receive either soap-and-water wipes (control group) or 2% chlorhexidine wipes (chlorhexidine group). Intention-to-treat data analysis was conducted from October 5, 2023, to April 24, 2024. INTERVENTION: Daily use of a 2% chlorhexidine wipe or a soap-and-water wipe on the feet for 1 year. Wipes were nearly identical in color, size, shape, thickness, feel, and scent. Both chlorhexidine and control groups received the same lotion for application on the feet after wipe use and education on foot self-care. MAIN OUTCOMES AND MEASURES: The primary outcome was time in days from randomization to new foot complication, including chronic foot ulcer, foot infection, or foot amputation. RESULTS: A total of 175 participants (170 males [97%]; mean [SD] age at enrollment, 68 [9] years; 1 Asian [1%], 117 Black or African American [67%], 53 White [30%] individuals) were randomly assigned to the chlorhexidine group (n = 88) or the control group (n = 87). Twelve participants (14%) in the chlorhexidine group and 14 participants (16%) in the control group developed a new foot complication within 1 year. Median (IQR) time from randomization to development of a new foot complication was 232 (115-315) days. The reduction in hazard of new foot complications in the chlorhexidine group compared with the control group was not significant (hazard ratio, 0.83; 95% CI, 0.39-1.80). The intervention was well tolerated, with 145 participants (83%) continuing it over the study period. Sixty adverse events occurred, but none was related to the study products or procedures. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that daily use of chlorhexidine wipes for foot washing for 1 year did not lead to a significant reduction in the risk of new foot complications compared with daily use of soap-and-water wipes. The intervention was well tolerated, and the trial provides important lessons for future studies on diabetic foot ulcer prevention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03503370.
2. Effects of dietary sources and personal care products on paraben exposure in young Korean adults: A crossover intervention study.
In a 6-day crossover intervention with 27 Korean college students using preservative-free personal care products, dietary sauces drove large changes in urinary paraben levels. Ethyl paraben fell by 79.7% on a paraben-free sauce diet and rose by 2830% when paraben-containing sauces were reintroduced, indicating diet is a dominant exposure source.
Impact: Shifts the focus of paraben exposure mitigation from personal care products to diet, especially ethyl paraben, informing risk assessment and regulatory priorities.
Clinical Implications: For individuals concerned about endocrine-active preservative exposure, counseling should include dietary sources (condiments/sauces) in addition to personal care product choices; biomonitoring studies should account for diet.
Key Findings
- Baseline urinary EtP levels (~76.9 ng/mL) were 3–14 times higher than reported in other countries.
- No significant change in urinary paraben levels after preservative-free CPCP use alone.
- EtP decreased by 79.7% (95% CI −89.2, −61.8) on a paraben-free sauce diet, then increased by 2830% (1310–5990) with paraben-containing sauces; MeP increased by 84.4% (25.7, 170).
Methodological Strengths
- Within-subject crossover design isolates dietary vs CPCP contributions
- Sensitive HPLC-MS/MS quantification of nine parabens with controlled CPCP exposure
Limitations
- Small sample size (n=27) and short 6-day intervention window
- Single-country, young adult cohort limits generalizability; dietary manipulations focused on sauces
Future Directions: Expand to larger, diverse cohorts with longer follow-up, detailed dietary records, and source apportionment; evaluate regulatory impacts of food additive parabens on population exposure.
Parabens including methyl-(MeP), ethyl-(EtP), and propyl-(PrP) parabens, are widely used as antimicrobial preservatives in foods, cosmetics, and personal care products (CPCPs), and drugs. However, studies evaluating the contribution of exposure sources to paraben exposure are limited, and most focus primarily on CPCPs. This study conducted a crossover intervention to assess the contributions of foods and CPCPs to paraben exposure among young Korean adults. Twenty-seven college students participated in a 6-day intervention. They used preservative-free CPCPs throughout the study and were served a 'diet with paraben-free sauces' on days 3-4, followed by a 'diet with paraben-containing sauces' on days 5-6. Urine samples collected at each intervention point were analyzed for nine parabens, including MeP, EtP, and normal propyl-paraben (nPrP), using HPLC-MS/MS. Before the intervention, the geometric mean urinary concentrations of MeP, EtP, and nPrP were 6.05, 76.9, and 0.52 ng/mL, respectively-approximately 3 to 14 times higher than levels reported in other countries. No significant changes in urinary paraben concentrations were observed after the CPCPs-only intervention. However, following the diet with paraben-free sauces, urinary EtP levels significantly decreased by 79.7% (95% CI -89.2, -61.8). After diet with paraben-containing sauces, urinary EtP and MeP levels increased significantly (EtP 2830% (1310-5990); MeP 84.4% (25.7, 170)). This study highlights the substantial impact of diet on paraben exposure, especially EtP, suggesting that dietary sources play a significant role.
3. Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome.
In 216 capecitabine-treated patients randomized to usual care versus usual care plus urea cream, prophylactic urea did not reduce any-grade or severe (≥grade 3) hand-foot syndrome, nor decrease capecitabine modifications or delay onset. A trend toward reduced severity in later cycles was noted.
Impact: Provides robust negative RCT evidence against routine prophylactic urea cream for capecitabine-associated HFS, guiding supportive care practices.
Clinical Implications: Do not rely on urea cream for HFS prophylaxis in capecitabine regimens; focus on patient education, early symptom reporting, dose management, and evaluate alternative preventive strategies.
Key Findings
- Any-grade HFS: 62.4% (68/109) usual care vs 56% (60/107) urea cream (p=0.36).
- Severe HFS (≥grade 3): 47.7% vs 41.1% (p=0.34).
- Capecitabine modification due to HFS: 18.3% vs 15.9% (p=0.89); onset timing similar between groups.
Methodological Strengths
- Randomized allocation with cycle-by-cycle prospective assessments
- Clinically meaningful endpoints including severe HFS and treatment modifications
Limitations
- Blinding and adherence monitoring not detailed; potential performance bias
- Single-cream formulation; results may not generalize to other emollients or concentrations
Future Directions: Test alternative preventive strategies (cooling, DPPIV inhibitors, barrier-enhancing agents), optimize dosing/timing, and identify high-risk subgroups for targeted prophylaxis.
BACKGROUND: Hand-foot syndrome (HFS) is a common adverse event of capecitabine causing treatment modifications. Topical urea cream can reduce sorafenib-induced hand-foot skin reaction. However, its benefit in preventing capecitabine-associated HFS was not seen early in the course and had been unknown with long-term use. The aim of this study was to evaluate the efficacy of urea cream for HFS prophylaxis throughout capecitabine treatment. METHODS: Patients with cancer who received capecitabine were randomized (1:1) to receive usual care alone or in combination with urea-based cream. The incidence and degree of HFS were assessed at each capecitabine cycle. The primary endpoint was the proportion of patients with any grade HFS. The secondary endpoints included the proportion of patients with severe (≥ grade 3) HFS, modifications in capecitabine because of HFS, and HFS onset. RESULTS: After a median of six capecitabine cycles, any grade HFS was reported by 68 of 109 patients (62.4%) who received usual care and by 60 of 107 patients (56%) who used urea cream (p = 0.36). The patients who received usual care and urea cream had similar proportions of grade 3 HFS occurrence [52 (47.7%) vs. 44 (41.1%), respectively, p = 0.34] and needed capecitabine modification because of HFS [20 patients (18.3%) vs. 17 patients (15.9%), respectively, p = 0.89], as well as similar HFS onset. CONCLUSIONS: Urea-based cream did not prevent capecitabine-associated HFS, reduce capecitabine modification, and delay HFS onset. However, it had a tendency to lessen HFS severity, especially in the later cycles of capecitabine. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT05348278, registered on April 21, 2022.